Impact of particle size of multivesicular liposomes on the embolic and therapeutic effects in rabbit VX2 liver tumor.

Publisher: Taylor & Francis Country of Publication: England NLM ID: 9417471 Publication Model: Print Cited Medium: Internet ISSN: 1521-0464 (Electronic) Linking ISSN: 10717544 NLM ISO Abbreviation: Drug Deliv Subsets: MEDLINE

Publication: 2015->: Abingdon, Oxford : Taylor & Francis
Original Publication: Orlando, FL : Academic Press, c1993-

Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/pathology ; Chemoembolization, Therapeutic*/methods ; Liver Neoplasms*/drug therapy ; Liver Neoplasms*/pathology; Animals ; Rabbits ; Doxorubicin ; Ethiodized Oil ; Liposomes ; Particle Size

Transcatheter arterial chemoembolization (TACE) is usually considered more efficacious in the local treatment of parenchyma-sparing hepatocellular carcinoma (HCC). At present, embolic agents commonly used in TACE, include DC pellets, Hepasphere, Lipiodol, etc. Except that iodine oil is a viscous fluid embolic agent, other solid microsphere particles used clinically range from 70 to 700 µm, among which 100 to 300 µm is the most commonly used. With the technology development of micro-invasive interventional therapy, the specific distal embolization through TACE to occlude tumor arterial blood supply in patients with HCC is also required more accurately. Effective terminal embolization is considered to be a preferred option for TACE therapy due to significantly improving the survival rate of patients and preserving liver function. In this article, we prepared the multifunctional multivesicular liposomes (IVO-DOX-MVLs) (<100 µm) that can simultaneously encapsulate ioversol and doxorubicin based on the high-phase transition temperature ( T m ) lipid ingredients, and evaluated its local artery embolization and therapeutic effect in rabbit VX-2 tumor model. The influence of particle size on occlusion and therapeutic effect of MVLs on rabbit VX-2 liver tumor models were well evaluated, including the tumor volume change, tumor growth rate, and necrosis rate, which were evaluated by magnetic resonance (MR). MVL samples with average particle size distribution of 50-60 µm exhibited fewer off-target embolization. Through TACE, IVO-DOX-MVLs were directly transported to the tumor tissues, playing roles of embolization performance, CT imaging effect, and local tumor killing effect. The feasibility of MVLs as a multifunctional embolic agent in its clinical application can be further improved by optimization of lipid composition and preparation process.

Pharm Dev Technol. 2013 Jul-Aug;18(4):828-33. (PMID: 22759074)
J Hepatol. 2007 Jul;47(1):157-8; author reply 159. (PMID: 17509721)
BMB Rep. 2021 Sep;54(9):470-475. (PMID: 34488932)
Korean J Radiol. 2015 Jan-Feb;16(1):125-32. (PMID: 25598680)
Theranostics. 2018 Aug 10;8(17):4591-4600. (PMID: 30279724)
J Vasc Interv Radiol. 2015 Jul;26(7):965-71. (PMID: 25979305)
Cancer Res. 2005 Aug 15;65(16):7045-51. (PMID: 16103050)
Adv Mater. 2019 Aug;31(33):e1901071. (PMID: 31168915)
Cancer Manag Res. 2021 Sep 07;13:6943-6952. (PMID: 34522137)
ACS Appl Mater Interfaces. 2017 Dec 20;9(50):43478-43489. (PMID: 29116741)
Cardiovasc Intervent Radiol. 2009 Mar;32(2):367-70. (PMID: 18931873)
J Pharm Pharmacol. 2011 Jul;63(7):904-10. (PMID: 21635255)
Prog Lipid Res. 2002 Sep;41(5):392-406. (PMID: 12121719)
Acta Pharmacol Sin. 2005 Nov;26(11):1395-401. (PMID: 16225764)
Eur J Radiol. 2012 Sep;81(9):1976-9. (PMID: 21628086)
Minim Invasive Ther Allied Technol. 2021 Aug;30(4):221-228. (PMID: 32031474)
Surg Endosc. 2019 Apr;33(4):1131-1139. (PMID: 30043170)
Oncology. 2022;100(6):303-312. (PMID: 35114665)
Abdom Radiol (NY). 2022 Feb;47(2):858-868. (PMID: 34820688)
Br J Radiol. 2011 Feb;84(998):184-7. (PMID: 21257838)
Drug Deliv. 2011 Jul;18(5):361-6. (PMID: 21428705)
Pharmaceutics. 2017 Mar 27;9(2):. (PMID: 28346375)
Front Oncol. 2022 Jul 08;12:909426. (PMID: 35875123)
Jpn J Radiol. 2021 May;39(5):494-502. (PMID: 33387186)
Pharmaceutics. 2021 Dec 17;13(12):. (PMID: 34959462)
Ann Hepatol. 2022 Sep-Oct;27(5):100729. (PMID: 35700935)
J Clin Med. 2021 Jul 17;10(14):. (PMID: 34300327)
J Nanobiotechnology. 2022 Apr 2;20(1):179. (PMID: 35366904)
J Vasc Interv Radiol. 2008 Jun;19(6):862-9. (PMID: 18503900)
J Belg Soc Radiol. 2022 Mar 10;106(1):10. (PMID: 35434518)
Pharmazie. 1992 Jun;47(6):439-43. (PMID: 1409841)
Eur Radiol. 2021 Oct;31(10):7512-7522. (PMID: 33871708)
Biophys J. 2004 Dec;87(6):3882-93. (PMID: 15377511)
Curr Vasc Pharmacol. 2009 Apr;7(2):250-63. (PMID: 19356008)
J Hepatocell Carcinoma. 2021 Aug 14;8:937-949. (PMID: 34422707)
Cancer Sci. 2008 Oct;99(10):2037-44. (PMID: 19016764)
Molecules. 2019 May 05;24(9):. (PMID: 31060345)
J Vasc Interv Radiol. 2013 Sep;24(9):1391-8. (PMID: 23891049)
Cancers (Basel). 2022 Jun 23;14(13):. (PMID: 35804861)
Nat Rev Cancer. 2004 Jun;4(6):423-36. (PMID: 15170445)
Eur Radiol. 2021 Nov;31(11):8291-8301. (PMID: 33893536)

Keywords: Embolic agent; TACE; metronome chemotherapy; multivesicular liposome; rabbit VX2 liver tumor

80168379AG (Doxorubicin)
8008-53-5 (Ethiodized Oil)
0 (Liposomes)

Date Created: 20230116 Date Completed: 20230117 Latest Revision: 20250205

20250206

PMC9987747

10.1080/10717544.2022.2157519

36644796